Amaury Daste

Durvalumab with or without tremelimumab in patients with recurrent or metastatic head and neck squamous cell carcinoma: EAGLE, a randomized, open-label phase III study

Robert L. Ferris, Robert I. Haddad, Caroline Even et al. · Annals of Oncology · 2020 · 358 citations · Full text

Safety and Efficacy of Durvalumab With or Without Tremelimumab in Patients With PD-L1–Low/Negative Recurrent or Metastatic HNSCC

Lillian L. Siu, Caroline Even, Éva Remenár et al. · JAMA Oncology · 2018 · 306 citations · Full text

Response to salvage chemotherapy after progression on immune checkpoint inhibitors in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck

Khalil Saleh, Amaury Daste, Nicolas Martin et al. · European Journal of Cancer · 2019 · 180 citations

Medicine, Immune Checkpoint Inhibitors, Immunology +8

Nivolumab Plus Ipilimumab Versus EXTREME Regimen as First-Line Treatment for Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck: The Final Results of CheckMate 651

Robert I. Haddad, Kevin J. Harrington, Makoto Tahara et al. · Journal of Clinical Oncology · 2022 · 142 citations · Full text

A multicenter phase II study of sunitinib in patients with locally advanced or metastatic differentiated, anaplastic or medullary thyroid carcinomas: mature data from the THYSU study

Alain Ravaud, Christelle de la Fouchardière, Philippe Caron et al. · European Journal of Cancer · 2017 · 107 citations

Thysu Study, Medicine, Medullary Thyroid Carcinomas +7